<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02420704</url>
  </required_header>
  <id_info>
    <org_study_id>RMCZZU-Endometrial thickness</org_study_id>
    <nct_id>NCT02420704</nct_id>
  </id_info>
  <brief_title>Effect of Endometrial Thickness on IVF Outcome</brief_title>
  <official_title>Effect of Endometrial Thickness on IVF Outcome: a Prospective Observational Study of Both Cleavage Stage and Blastocyst Stage Embryo Transfer Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Zhengzhou University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although many studies have evaluated the relationship between endometrial thickness and IVF
      outcome, the results are still controversial. We notice that, during our daily work, for
      patients undergoing cleavage stage embryo transfer, endometrial thickness seems to have a
      huge impact on IVF outcome; however, for blastocyst stage embryo transfers, IVF outcome seems
      to have little association with endometrial thickness. Thus, the aim of this prospective
      observational study is to explore the relationship between endometrial thickness and IVF
      outcome in patients undergoing cleavage stage and blastocyst stage embryo transfers,
      respectively.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>12 weeks after embryo transfer</time_frame>
    <description>An ongoing pregnancy was defined as a pregnancy with a positive heartbeat by ultrasound after 12 weeks gestation.</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Cleavage stage-thin endometrial</arm_group_label>
    <description>Patients transferred with cleavage stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cleavage stage-medium endometrial</arm_group_label>
    <description>Patients transferred with cleavage stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cleavage stage-thick endometrial</arm_group_label>
    <description>Patients transferred with cleavage stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blastocyst stage-thin endometrial</arm_group_label>
    <description>Patients transferred with blastocyst stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blastocyst stage-medium endometrial</arm_group_label>
    <description>Patients transferred with blastocyst stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blastocyst stage-thick endometrial</arm_group_label>
    <description>Patients transferred with blastocyst stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Embryo transfer</intervention_name>
    <description>For fresh cycles, embryos were transferred 3-5 days after oocyte retrieval; For frozen thawed cycles, embryos were transferred 3-5 days after starting to use progesterone based on the stage of cryopreservation.</description>
    <arm_group_label>Cleavage stage-thin endometrial</arm_group_label>
    <arm_group_label>Cleavage stage-medium endometrial</arm_group_label>
    <arm_group_label>Cleavage stage-thick endometrial</arm_group_label>
    <arm_group_label>Blastocyst stage-thin endometrial</arm_group_label>
    <arm_group_label>Blastocyst stage-medium endometrial</arm_group_label>
    <arm_group_label>Blastocyst stage-thick endometrial</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients transfrred with at least two high quality cleavage stage embryos, or with at least
        one high quality blastocyst stage embryo.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 22-38 years old;

          -  the first cycle of IVF treatment with standard long protocol;

          -  transfrred with at least two high quality cleavage stage embryos, or with at least one
             high quality blastocyst stage embryo.

        Exclusion Criteria:

          -  PGD cycles;

          -  gamete donation cycles
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yingpu Sun, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reproductive Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhiqin Bu, M.D</last_name>
    <phone>86-15981978863</phone>
    <email>rmczzu@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yingpu Sun, M.D</last_name>
    <phone>86-13503841888</phone>
    <email>syp2008@vip.sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingpu Ms Sun, M.D,PhD</last_name>
      <phone>86-13803841888</phone>
      <email>syp2008@vip.sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhiqin Mr Bu, MD</last_name>
      <phone>86-15981978863</phone>
      <email>rmczzu@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wu Y, Gao X, Lu X, Xi J, Jiang S, Sun Y, Xi X. Endometrial thickness affects the outcome of in vitro fertilization and embryo transfer in normal responders after GnRH antagonist administration. Reprod Biol Endocrinol. 2014 Oct 9;12:96. doi: 10.1186/1477-7827-12-96.</citation>
    <PMID>25296555</PMID>
  </reference>
  <reference>
    <citation>Zhao J, Zhang Q, Wang Y, Li Y. Endometrial pattern, thickness and growth in predicting pregnancy outcome following 3319 IVF cycle. Reprod Biomed Online. 2014 Sep;29(3):291-8. doi: 10.1016/j.rbmo.2014.05.011. Epub 2014 Jun 13.</citation>
    <PMID>25070912</PMID>
  </reference>
  <reference>
    <citation>Kasius A, Smit JG, Torrance HL, Eijkemans MJ, Mol BW, Opmeer BC, Broekmans FJ. Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis. Hum Reprod Update. 2014 Jul-Aug;20(4):530-41. doi: 10.1093/humupd/dmu011. Epub 2014 Mar 23. Review.</citation>
    <PMID>24664156</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2015</study_first_submitted>
  <study_first_submitted_qc>April 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <last_update_submitted>April 18, 2015</last_update_submitted>
  <last_update_submitted_qc>April 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Yingpu Sun</investigator_full_name>
    <investigator_title>Director of Reproductive Medical Center</investigator_title>
  </responsible_party>
  <keyword>IVF</keyword>
  <keyword>endometrial thickness</keyword>
  <keyword>cleavage stage embryo</keyword>
  <keyword>blastocyst stage embryo</keyword>
  <keyword>Ongoing pregnancy rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

